Fig. 5From: The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registryProportion of patients with CRP level ≤ 0.3 mg/dL at month 6. CRP, C-reactive protein; IL-6Ri, interleukin-6 receptor inhibitor; JAKi, Janus kinase inhibitor; TNFi, tumor necrosis factor inhibitorBack to article page